ArticleBMC cancer2024
TACE combined Lenvatinib plus Camrelizumab versus TACE alone in efficacy and safety for unresectable hepatocellular carcinoma: a propensity score-matching study.
Article in BMC cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Comparative efficacy of combination regimens based on interventional therapy and immune checkpoint inhibitors (ICIs) in patients with intermediate- and advanced-stage hepatocellular carcinoma: a systematic review, meta-analysis, and network meta-analysis.Cancer immunology, immunotherapy : CII · 2026Pooled it
- Efficacy of PD-1/PD-L1 inhibitors combined with anti-VEGF/TKIs and TACE in uHCC: a meta-analysis.Frontiers in oncology · 2026Pooled it
- Comparison of the efficacy of transarterial chemoembolization combined with different molecular targeted agents and/or immune checkpoint inhibitors for unresectable hepatocellular carcinoma: a systematic review and network meta-analysis.Journal of gastrointestinal oncology · 2026Article
- Tailored Internet-Delivered Mindfulness-Based Interventions for Patients With Hepatocellular Carcinoma After Transarterial Chemoembolization: Qualitative Study.Journal of medical Internet research · 2026Article
- Impact of TACE combined with targeted and immune therapy on liver function and prognosis in unresectable hepatocellular carcinoma patients: the significance of baseline albumin-bilirubin grade.Therapeutic advances in medical oncology · 2026Article
- Survival impact of conversion therapy for Barcelona Clinic Liver Cancer (BCLC) stage B and C hepatocellular carcinoma-a propensity score matching analysis.Hepatobiliary surgery and nutrition · 2025Article
- Comprehensive Review of Transarterial Chemoembolization Plus Systemic Therapy in Advanced Hepatocellular Carcinoma.Journal of gastrointestinal cancer · 2025Review
- Efficacy and safety of radiotherapy versus transarterial chemoembolization in combination with lenvatinib and camrelizumab for hepatocellular carcinoma with inferior vena cava/right atrium tumor thrombus: a multicenter study.Hepatology international · 2025Article
- The Combined Use of Lenvatinib and Locoregional Therapies for the Management of Hepatocellular Carcinoma.Cancers · 2025Review
- Efficacy and Safety Analysis of Transarterial Chemoembolization Combined with Sintilimab Plus Bevacizumab Biosimilar in the Treatment of Unresectable Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundsTo compare the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined Lenvatinib plus Camrelizumab (TLC) in unresectable hepatocellular carcinoma (uHCC) with those of TACE alone .
methodsA retrospective analysis was performed on 222 patients with uHCC who were treated between September 2013 and Jun 2023. One group received TACE + lenvatinib + camrelizumab (TLC) (n = 97) and another group received TACE alone (n = 151). Efficacy and safety were compared after propensity score matching between the TLC and TACE groups.
resultsAfter propensity matching, the TLC group had higher objective response rate (ORR) (88.6% vs. 28.6%, P < 0.001), disease control rate (DCR) (94.3%% vs. 72.9%, P < 0.001), and conversion rates before and after propensity matching were 44.1% and 41.4%, respectively, compared with the TACE group. The median progression free survival (PFS) was longer in the TLC group than in the TACE group (12.7 vs. 6.1 months, P = 0.005). The median overall survival (OS) was longer in the TLC group than in the TACE group (19.4 vs. 13.0 months, P = 0.023). Cox multivariate analysis with different modes of adjustment showed that treatment was an independent influencing factor of PFS and OS. The interaction analysis showed that cirrhosis and Child-Pugh stage an interactive role in the PFS of different treatment. Decreased AFP after treatment portends higher ORR and DCR.
conclusionTACE combined Lenvatinib plus Camrelizumab regimen was safe and superior to TACE alone in improving PFS, OS, and tumor response rates for unresectable recurrent HCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.